Association of serum vaspin and adiponectin levels with renal function in patients with or without type 2 diabetes mellitus

Journal of Diabetes Research

Volumn 2014, Issue , 2014, Pages

  Yan, Meiyu ^a   Su, Bin ^a   Peng, Wenhui ^a   Li, Liang ^a   Li, Hailing ^a   Zhuang, Jianhui ^a   Lu, Yuyan ^a   Jian, Weixia ^b   Wei, Yidong ^a   Li, Weiming ^a   Qu, Shen ^a   Xu, Yawei ^a  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; VASPIN; ADIPOQ PROTEIN, HUMAN; BIOLOGICAL MARKER; SERINE PROTEINASE INHIBITOR; SERPINA12 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; DIABETIC PATIENT; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RENAL INSUFFICIENCY; VERY ELDERLY;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY; SERPINS;

EID: 84928771399     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2014/868732     Document Type: Article

References (34)

1. K. Hida, J. Wada, J. Eguchi, et al., "Visceral adipose tissuederived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 30, pp. 10610-10615, 2005.
2. M. Blüher, "Vaspin in obesity and diabetes: pathophysiological and clinical significance, " Endocrine, vol. 41, no. 2, pp. 176-182, 2012.
3. Z. Dastani, M.-F. Hivert, N. Timpson, et al., "Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45, 891 individuals, " PLoS Genetics, vol. 8, no. 3, Article ID e1002607, 2012.
4. S. H. Choi, S. H. Kwak, Y. Lee, et al., "Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women, " Clinical Endocrinology, vol. 75, no. 5, pp. 628-635, 2011.
5. F. C. Brosius III, T. H. Hostetter, E. Kelepouris, et al., "Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: A science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group, " Circulation, vol. 114, no. 10, pp. 1083-1087, 2006.
6. E. E. Kershaw and J. S. Flier, "Adipose tissue as an endocrine organ, " Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2548-2556, 2004.
7. N. E. Gulcelik, A. Usman, and A. Gürlek, "Role of adipocytokines in predicting the development of diabetes and its late complications, " Endocrine, vol. 36, no. 3, pp. 397-403, 2009.
8. J. Inoue, J. Wada, S. Teshigawara, et al., "The serumvaspin levels are reduced in Japanese chronic hemodialysis patients, " BMC Nephrology, vol. 13, article 163, 2012.
9. H. L. Li, W. H. Peng, S. T. Cui, et al., "Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris, " Clinical Chemistry and Laboratory Medicine, vol. 49, no. 9, pp. 1547-1554, 2011.
10. D. W. Cockcroft and M. H. Gault, "Prediction of creatinine clearance fromserum creatinine, " Nephron, vol. 16, no. 1, pp. 31-41, 1976.
11. F. C. Brosius III, T. H. Hostetter, E. Kelepouris, et al., "Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in Collaboration with the National Kidney Foundation, " Circulation, vol. 114, no. 10, pp. 1083-1087, 2006.
12. M. Blüher, "Adipose tissue dysfunction in obesity, " Experimental and Clinical Endocrinology & Diabetes, vol. 117, no. 6, pp. 241-250, 2009.
13. P. G. W. Gettins, "Serpin structure, mechanism, and function, " Chemical Reviews, vol. 102, no. 12, pp. 4751-4803, 2002.
14. R. H. P. Law, Q. Zhang, S. McGowan, et al., "An overview of the serpin superfamily, " Genome Biology, vol. 7, article 216, no. 5, 2006.
15. G. A. Silverman, P. I. Bird, R. W. Carrell, et al., "The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revisednomenclature, "TheJournal of Biological Chemistry, vol. 276, no. 36, pp. 33293-33296, 2001.
16. B. Youn, N. Klöting, J. Kratzsch, et al., "Serum vaspin concentrations in human obesity and type 2 diabetes, " Diabetes, vol. 57, no. 2, pp. 372-377, 2008.
17. N. Klöting, J. Berndt, S. Kralisch, et al., "Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes, " Biochemical and Biophysical Research Communications, vol. 339, no. 1, pp. 430-436, 2006.
18. S. Phalitakul, M. Okada, Y. Hara, and H. Yamawaki, "Vaspin prevents TNF-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependentNF-κB andPKCθ activation in cultured rat vascular smooth muscle cells, " Pharmacological Research, vol. 64, no. 5, pp. 493-500, 2011.
19. C. H. Jung, W. J. Lee, J. Y. Hwang, et al., "Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells, " PLoS ONE, vol. 7, no. 12, Article ID e52346, 2012.
20. S. Phalitakul, M. Okada, Y. Hara, and H. Yamawaki, "A novel adipocytokine, vaspin inhibits platelet-derived growth factor-BB-induced migration of vascular smooth muscle cells, " Biochemical and Biophysical Research Communications, vol. 423, no. 4, pp. 844-849, 2012.
21. J. J. Carrero, A. C. Cordeiro, B. Lindholm, and P. Stenvinkel, "The emerging pleiotrophic role of adipokines in the uremic phenotype, " Current Opinion in Nephrology and Hypertension, vol. 19, no. 1, pp. 37-42, 2010.
22. Y. Ye, X. H. Hou, X. P. Pan, J. X. Lu, and W. Jia, "Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes, " Chinese Medical Journal, vol. 122, no. 21, pp. 2530-2533, 2009.
23. L. Zhang, L. Li, M. Yang, H. Liu, and G. Yang, "Elevated circulating vaspin levels were decreased by rosiglitazone therapy in T2DM patients with poor glycemic control on metformin alone, " Cytokine, vol. 56, no. 2, pp. 399-402, 2011.
24. M. A. Kobat, A. Celik, M. Balin, et al., "The investigation of serum vaspin level in atherosclerotic coronary artery disease, " Journal of Clinical Medicine Research, vol. 4, no. 2, pp. 110-113, 2012.
25. G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, "Adipose expression of tumor necrosis factor-: direct role in obesity-linked insulin resistance, " Science, vol. 259, no. 5091, pp. 87-91, 1993.
26. Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman, "Positional cloning of the mouse obese gene and its human homologue, " Nature, vol. 372, no. 6505, pp. 425-432, 1994.
27. M. A. Lazar, "The humoral side of insulin resistance, " Nature Medicine, vol. 12, no. 1, pp. 43-44, 2006.
28. H. J. McCourt, S. J. Hunter, C. R. Cardwell, et al., "Adiponectin multimers, body weight and markers of cardiovascular risk in adolescence: Northern Ireland Young Hearts Project, " International Journal of Obesity, vol. 37, no. 9, pp. 1247-1253, 2013.
29. T. Kadowaki and T. Yamauchi, "Adiponectin and adiponectin receptors, " Endocrine Reviews, vol. 26, no. 3, pp. 439-451, 2005.
30. T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki, and K. Tobe, "Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome, " Journal of Clinical Investigation, vol. 116, no. 7, pp. 1784-1792, 2006.
31. Y. Arita, S. Kihara, N. Ouchi, et al., "Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity, " Biochemical and Biophysical Research Communications, vol. 257, no. 1, pp. 79-83, 1999.
32. Y. Matsuzawa, "Establishment of a concept of visceral fat syndrome and discovery of adiponectin, " Proceedings of the Japan Academy B: Physical and Biological Sciences, vol. 86, no. 2, pp. 131-141, 2010.
33. C. S. Chu, K. T. Lee, M. Y. Lee, et al., "Effects of Rosiglitazone alone and in combination with Atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus, " The American Journal of Cardiology, vol. 97, no. 5, pp. 646-650, 2006.
34. C. Da-Wa, F. Zhao, Y. Qi, L. Chen, and Y. Huo, "Role of adiponectin and its receptors in anti-atherosclerotic effects of pioglitazone on ApoE knocked out mice, " Beijing Da Xue Xue Bao. Yi Xue Ban, vol. 41, no. 2, pp. 174-178, 2009.